Attractive programs with high clinical value.

Today, Ligand manages one of the largest and most diverse portfolios of biopharmaceutical royalties in the industry, with more than 85 partnered commercial and development stage programs. 

The assets in our portfolio include treatments for cancer, kidney disease, diabetes, nonalcoholic steatohepatitis, and other rare conditions that threaten lifespan and quality of life for billions of people. More than 25 of these are approved medications and are available to patients around the world.

Key Commercial Products

Product PartnerTherapy AreaStageRoyalty Rate
EVOMELA®Acrotech Biopharma / CASI Pharmaceuticals Oncology Marketed20%
FILSPARI™Travere TherapeuticsKidney DiseaseMarketed9%
Kyprolis®AmgenOncology Marketed1.5%-3%
PNEUMOSIL®Serum Institute of IndiaInfectious DiseaseMarketedLow single-digit
RYLAZE®Jazz PharmaceuticalsOncology MarketedLow single-digit
Teriparatide Injection AlvogenEndocrinologyMarketed25-50%
TZIELD®SanofiEndocrinologyMarketedLess than 1%
VAXNEUVANCE™ MerckInfectious DiseaseMarketedLow single-digit
ZELSUVMI™Pelthos TherapeuticsInfectious DiseaseApprovedN/A

Key Pipeline Products

Product PartnerTherapy AreaStageRoyalty Rate
EnsifentrineVerona PharmaRespiratory DiseaseNDALow single-digit
Ganaxalone IVMarinus Pharmaceuticals CNSPhase 3Low to mid-single digit
QTORIN™Palvella TherapeuticsRare Disease Phase 38%-9.8%
SoticlestatTakedaCNSPhase 3Tiered up to 2.6%
V116MerckInfectious DiseasePhase 3Low single-digit
VK2809Viking Therapeutics HepatologyPhase 23.5%-7.5%

Additional Products

Product PartnerTherapy AreaStageRoyalty Rate
ACLX-001ArcellxOncology Phase 1Undisclosed
ACLX-002ArcellxOncology Phase 1Undisclosed
ACR-368 (CHK1/CHK2)AcrivonOncology Phase 2Undisclosed
ALTO-101Alto NeuroscienceNeurologyPhase I/IIUndisclosed
BAXDELA®Melinta Therapeutics Infectious DiseaseMarketed2.5%
Bryxta and ZybevZydus CadilaOncology MarketedUndisclosed
CE-furosemideSQ InnovationCardiology NDAUndisclosed
CE-MeloxicamApotexNeurologyPhase 1Undisclosed
Ciforadenant (CPI-444) Corvus Pharmaceuticals Oncology Phase 2Mid-single digit to low-teens
CX2101ACR Double-Crane PharmaceuticalsInfectious DiseasePhase 1Undisclosed
DUAVEE®PfizerMenopauseMarketed0.5% – Less than $400M
1.5% – Sales from $400M - $1.0B
2.5% – Sales greater than $1.0B
ExemptiaZydus CadilaInflammatory DiseaseMarketedUndisclosed
FrovatriptanMenariniNeurologyMarketedUndisclosed
FYCOMPA®EisaiCNSMarketedUndisclosed
LasofoxifeneSermonix Pharmaceuticals Oncology Phase 36%-10%
MB07133Xi'an XintongOncology Phase 26%
ME-344MEI Pharmaceuticals Oncology Phase 1Low single-digit
MIK665NovartisOncology Phase 1Undisclosed
MINNEBRO®Exelixis/Daiichi SankyoMetabolic DiseaseMarketedUndisclosed
NEXTERONEBaxterCardiology MarketedUndisclosed
NOXAFIL®Merck Infectious DiseaseMarketedMaterial sales only
NUC-1010Nucorion Pharmaceuticals Hepatology Phase 14%-9%
ONS-5010Outlook TherapeuticsOpthamologyNDAUndisclosed
OPT-302OptheaOpthamologyPhase 3Undisclosed
PosaconazolePar PharmaceuticalsInfectious DiseaseMarketedUndisclosed
PradefovirXi'an XintongInfectious DiseaseNDA9%
PTR-01 Phoenix Tissue RepairGenetic DiseasePhase 2Undisclosed
ReproxalapAldeyra Therapeutics OpthamologyNDAUndisclosed
REV-0100Revision TherapeuticsOpthamologyPhase 1Undisclosed
SAGE-689Sage Therapeutics CNSPhase 1Undisclosed
TAK-243TakedaOncology Phase 1Undisclosed
TAK-925TakedaCNSPhase 2Undisclosed
TeberifBiocadHematologyMarketedUndisclosed
Topiramate InjectionCURx PharmaceuticalsCNSPhase 1Mid-single digit
VEKLURY® (remdesivir)GileadInfectious DiseaseMarketedMaterial sales only
VilazodoneSunshine Lake PharmaCNSNDAUndisclosed
VirightJupiter BiomedOncology Phase 1Undisclosed
VivitraZydus CadilaOncology MarketedUndisclosed
Viviant®/Conbriza®PfizerOsteoporosisMarketed0.5%-2.5%
V117MerckInfectious DiseasePhase 1Undisclosed
VK0214Viking Therapeutics Rare DiseasePhase 1Undisclosed
VK1430Viking Therapeutics Metabolic DiseasePreclinical3%-7%
VK5211 Viking Therapeutics Musculoskeletal DisorderPhase 27.25%-9.25%
VoriconazoleNanjing King-FriendInfectious DiseaseMarketedUndisclosed
Voriconazole (EU)Hikma PharmaceuticalsInfectious DiseaseMarketedUndisclosed
VoriconazoleAlvogenInfectious DiseaseMarketedMaterial sales only
VortuxiZydus CadilaRheumatologyMarketedUndisclosed
ZULRESSO®Sage Therapeutics CNSMarketed3%

Note: The portfolio listed above includes only disclosable programs. Information regarding partnered products and programs comes from information publicly released by our partners.